scholarly journals Blackcurrant Improves Diabetic Cardiovascular Dysfunction by Reducing Inflammatory Cytokines in Type 2 Diabetes Mellitus Mice

Nutrients ◽  
2021 ◽  
Vol 13 (11) ◽  
pp. 4177
Author(s):  
Hye-Yoom Kim ◽  
Jung-Joo Yoon ◽  
Hyeon-Kyoung Lee ◽  
Ai-Lin Tai ◽  
Yun-Jung Lee ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Inflammatory Cytokines ◽  
Cardiovascular Complications ◽  
Extracellular Matrix Protein ◽  
Protein Accumulation ◽  
Cardiovascular Dysfunction ◽  
Cardiovascular Fibrosis

Diabetic cardiovascular dysfunction is a representative complication of diabetes. Inflammation associated with the onset and exacerbation of type 2 diabetes mellitus (T2DM) is an essential factor in the pathogenesis of diabetic cardiovascular complications. Diabetes-induced myocardial dysfunction is characterized by myocardial fibrosis, which includes structural heart changes, myocardial cell death, and extracellular matrix protein accumulation. The mice groups in this study were divided as follows: Cont, control (db/m mice); T2DM, type 2 diabetes mellitus mice (db/db mice); Vil.G, db/db + vildagliptin 50 mg/kg/day, positive control, dipeptidyl peptidase-4 (DPP-4) inhibitor; Bla.C, db/db + blackcurrant 200 mg/kg/day. In this study, Bla.C treatment significantly improved the homeostatic model evaluation of glucose, insulin, and insulin resistance (HOMA-IR) indices and diabetic blood markers such as HbA1c in T2DM mice. In addition, Bla.C improved cardiac function markers and cardiac thickening through echocardiography. Bla.C reduced the expression of fibrosis biomarkers, elastin and type IV collagen, in the left ventricle of a diabetic cardiopathy model. Bla.C also inhibited TD2M-induced elevated levels of inflammatory cytokines in cardiac tissue (IL-6, IL-1β, TNF-α, and TGF-β). Thus, Bla.C significantly improved cardiac inflammation and cardiovascular fibrosis and dysfunction by blocking inflammatory cytokine activation signals. This showed that Bla.C treatment could ameliorate diabetes-induced cardiovascular complications in T2DM mice. These results provide evidence that Bla.C extract has a significant effect on the prevention of cardiovascular fibrosis, inflammation, and consequent diabetes-induced cardiovascular complications, directly or indirectly, by improving blood glucose profile.

scholarly journals Inflammatory cytokines in type 2 diabetes mellitus as facilitators of hypercoagulation and abnormal clot formation

2019 ◽  
Vol 18 (1) ◽  
Author(s):  
Shehan N. Randeria ◽  
Greig J. A. Thomson ◽  
Theo A. Nell ◽  
Timothy Roberts ◽  
Etheresia Pretorius
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Inflammatory Cytokines ◽  
Clot Formation

P-selectin gene genotypes or haplotypes and cardiovascular complications in type 2 diabetes mellitus

2006 ◽  
Vol 16 (6) ◽  
pp. 418-425 ◽  
Author(s):  
G. Zalewski ◽  
E. Ciccarone ◽  
A. Di Castelnuovo ◽  
F. Zito ◽  
F. Capani ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Cardiovascular Complications

scholarly journals Genetic Susceptibility Contributes to Renal and Cardiovascular Complications of Type 2 Diabetes Mellitus

Hypertension ◽  
2006 ◽  
Vol 48 (1) ◽  
pp. 8-13 ◽  
Author(s):  
Barry I. Freedman ◽  
Donald W. Bowden ◽  
Michèle M. Sale ◽  
Carl D. Langefeld ◽  
Stephen S. Rich
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Genetic Susceptibility ◽  
Cardiovascular Complications

scholarly journals Genetic Relationship Between Interleukın-6 rs1800796 Variants,  Interleukın-6 Plasma Levels and Susceptibility to Type 2 Diabetes Mellitus and Diabetic Nephropathy

2021 ◽  
Author(s):  
Nezaket COBAN ◽  
Aysegul Bayramoglu ◽  
Zeynep TEMIZ
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Diabetic Nephropathy ◽  
Inflammatory Cytokines ◽  
Interleukin 6 ◽  
Enzyme Linked Immunosorbent Assay ◽  
Control Group ◽  
Significant Difference

Abstract Type 2 diabetes mellitus (T2DM) is very common worldwide and genetically heterogeneous. One of the microvascular complications is diabetic nephropathy (DN). In recent years, T2DM has been described as a disease caused by chronic inflammation. The imbalance between pro- and anti-inflammatory cytokines causes inflammation. One of the candidate genes associated with T2DM and DN is the Interleukin-6 (IL-6) gene, one of the pro-inflammatory cytokines. This study was conducted to determine the polymorphism frequencies of the IL-6 gene rs1800796 and investigate the role of this polymorphism in the development of T2DM and DN. Genomic DNA that was obtained from 261 people was used in the study. IL-6 gene rs1800796 polymorphism was determined using the PCR, restriction fragment length polymorphism (RFLP) and electrophoresis. IL-6 gene PCR products were discontinued by treatment with restriction enzyme BsrBI and were analyzed in 2% agarose gel electrophoresis. IL-6 (Bioassay technology laboratory, Shangai, China) level was examined by enzyme-linked immunosorbent assay (ELISA) using a commercial kit. The results were statistically analyzed. The frequencies of rs1800796 genotypes were found to be GG 70.7%, GC 28.5%, CC 0.8% in the control group and GG 87.8%, GC 9.9 %, CC 2.3% in T2DM patients. Although there was a statistically significant difference between the control group and the T2DM patient group in genotype and allele frequencies, there was no significant difference in DN. The G allele frequency was also significantly higher in the T2DM group (p=0.000). IL-6 levels were determinated increased in patients with Type-2 diabetes compared to the control group. However; there was no significant statistically. We can say that IL-6 rs1800796 polymorphism is related to T2DM and G allele can be used as a useful genetic marker; this polymorphism is not related to DN, though.

scholarly journals INTERLEUKIN LEVELS IN PATIENTS WITH ESSENTIAL HYPERTENSION COMBINED WITH TYPE 2 DIABETES MELLITUS

2019 ◽  
Vol 6 (1) ◽  
pp. 38-42
Author(s):  
B.O. Shelest
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Essential Hypertension ◽  
Interleukin 6 ◽  
Inflammatory Marker ◽  
Cardiovascular Complications ◽  
The Relationship ◽  
Diabetes And Obesity

INTERLEUKIN LEVELS IN PATIENTS WITH ESSENTIAL HYPERTENSION COMBINED WITH TYPE 2 DIABETES MELLITUSShelest B.O.The problem of combined course of hypertension of diabetes mellitus type 2 and obesity is becoming more common. This variant of comorbidity crucially increases the risk of cardiovascular complications. Inflammation is considered as an important link between the progression of hypertension and the development of adverse events. This study is devoted to the question of the relationship between the pro-inflammatory marker interleukin-6 and the increased blood pressure in patients with concomitant diabetes and obesity. The treatment of such patients with combined pathology remains the actual and difficult issue of medical practice. The article analyses the dynamics of interleukin-6 in the process of treatment with a fixed triple antihypertensive combination. Key words: hypertension, interleukin-6, type 2 diabetes mellitus, obesity. РІВНІ ІНТЕРЛЕЙКІНІВ У ХВОРИХ НА ГІПЕРТОНІЧНУ ХВОРОБУ У ПОЄДНАННІ З ЦУКРОВИМ ДІАБЕТОМ 2 ТИПУ Шелест Б.О.Все більшого поширення набуває проблема поєднаного перебігу гіпертензії цукрового діабету 2 типу та ожиріння. Такий варіант коморбидности різко підвищує ризик кардіоваскулярних ускладнень. Важливою ланкою в прогресуванні гіпертензії і розвитку несприятливих подій відводиться запаленню. Дана робота присвячена питанню залежності прозапального маркера інтерлейкіну-6 і підвищених цифр артеріального тиску у хворих з супутнім цукровим діабетом 2 типу і ожирінням. Актуальним і складним питанням медичної практики залишається лікування таких пацієнтів з поєднаною патологією. У статті аналізується динаміка інтерлейкіну-6 в процесі лікування потрійною фіксованою антигіпертензивною комбінацією.Ключові слова: гіпертонічна хвороба, інтерлейкін-6, цукровий діабет 2 типу, ожиріння. УРОВЕНЬ ИНТЕРЛЕЙКИНОВ У ПАЦИЕНТОВ С ГИПЕРТОНИЧЕСКОЙ БОЛЕЗНЬЮ В СОЧЕТАНИИ С САХАРНЫМ ДИАБЕТОМ 2 ТИПА. Шелест Б.А.Все большее распространение приобретает проблема сочетанного течения гипертензии сахарного диабета 2 типа и ожирения. Такой вариант коморбидности резко повышает риск кардиоваскулярных осложнений. Важным звеном в прогрессировании гипертензии и развитии неблагоприятных событий отводится воспалению. Даннаяработапосвящена вопросу зависимости провоспалительного маркера интерлейкина-6 и наличием повышенных цифр артериального давления у больных с сопутствующим сахарным диабетом и ожирением. Актуальным и сложным вопросом медицинской практики остается лечение таких пациентов с сочетанной патологией. В статье анализируется динамика интерлейкина-6 в процессе лечения фиксированной тройной антигипертензивной комбинацией. Ключевые слова: гипертоническая болезнь, интерлейкин-6, сахарный диабет 2 типа, ожирение.

Sign in / Sign up

Export Citation Format

Share Document